Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Sirtex Medical Ltd. (OTC: SXMDF).

Full DD Report for SXMDF

You must become a subscriber to view this report.


Recent News from (OTC: SXMDF)

Eisai (ESALY) Present On Expanding Existing Collaboration With Biogen - Slideshow
mThe following slide deck was published by Eisai Co., Ltd. ADR in conjunction with this Read more ...
Source: SeekingAlpha
Date: October, 24 2017 14:02
Sirtex Medical's (SXMDF) CEO Andrew McLean on Q4 2017 Results - Earnings Call Transcript
Sirtex Medical Ltd. (SXMDF) Q4 2017 Earnings Conference Call August 22, 2017 19:15 ET Executives Andrew McLean - Chief Executive Officer Darren Smith - Chief Financial Officer David Cade - Chief Medical Officer Analysts Andrew Goodsall - UBS David Stanton - CLSA Patrick...
Source: SeekingAlpha
Date: August, 24 2017 09:08
Sirtex Medical reports FY results
Sirtex Medical  ( OTCPK:SXMDF ): FY EPS of -$0.455 Revenue of $234.28M (+0.8% Y/Y) Press Release More news on: Sirtex Medical Ltd., Earnings news and commentary, Tech stocks news, ,
Source: SeekingAlpha
Date: August, 22 2017 23:47
New Analysis Reveals First-Line Treatment Data on SIR-Spheres® Y-90 Resin Microspheres for Patients with Liver Metastases from Right-Sided Primary Colon Cancer
BARCELONA, Spain , July 3, 2017 /PRNewswire/ -- SIRFLOX and FOXFIRE Global findings suggest that adding liver-directed Selective Internal Radiation Therapy (SIRT) to standard first-line chemotherapy may improve overall survival in metastatic colorectal cancer (mCRC) patients with righ...
Source: PR Newswire
Date: July, 03 2017 03:30
SIR-Spheres® Y-90 Resin Microspheres Showed No Significant Difference in Overall Survival (OS) Compared to Sorafenib in Advanced HCC with Significantly Fewer Severe Adverse Events, New Asia-Pacific Study Finds
CHICAGO , June 5, 2017 /PRNewswire/ -- Final Results of SIRveNIB Study presented at   2017 American Society of Clinical Oncology Meeting For the second time in less than two months, a major head-to-head study has shown that SIR-Spheres Y-90 resin microspheres, administered on...
Source: PR Newswire
Date: June, 05 2017 09:27
Metastatic Colorectal Cancer Patients Treated First-line With SIR-Spheres® Y-90 Resin Microspheres More Likely to Become Candidates for Potentially Curative Liver Surgery, REsect Study Shows
MAINZ, Germany , May 24, 2017 /PRNewswire/ -- Surgeons' blinded assessment of pre- and post-treatment CT scans of patients with previously unresectable colorectal cancer liver metastases treated in the SIRFLOX study presented at 12 th Annual European-African HPB meeting Adding select...
Source: PR Newswire
Date: May, 24 2017 03:09
Sirtex Trial Miss Means Beads Could Stay As Back-Up
Quality over quantity is a useful maxim, but not always when it comes to cancer patients' survival. The radioactive microbeads developed by Sirtex Medical (SRXTY) (SXMDF) did not increase overall survival of hepatocellular carcinoma patients over the standard of care, Bayer's (BAYRY) Nexavar, ...
Source: SeekingAlpha
Date: April, 26 2017 08:51
Sirtex Medical (SXMDF) Presents SARAH Clinical Study Results - Slideshow
The following slide deck was published by Sirtex Medical Ltd. in conjunction with this Read more ...
Source: SeekingAlpha
Date: April, 24 2017 11:41
SIR-Spheres® Y-90 Resin Microspheres Substantially Improves Quality of Survival in Primary Liver Cancer, New Study Against Standard Treatment Shows
AMSTERDAM , April 24, 2017 /PRNewswire/ -- 459-patient SARAH Study shows that local treatments of advanced or inoperable Hepatocellular Cancer (HCC) with SIR-Spheres Y-90 resin microspheres did not lead to a planned superiority difference in overall survival compared t...
Source: PR Newswire
Date: April, 24 2017 02:00
SIR-Spheres(R) Y-90 Resin Microspheres Substantially Improves Quality of Survival in Primary Liver Cancer, New Study Against Standard Treatment Shows
AMSTERDAM , April 24, 2017 /PRNewswire/ -- 459-patient SARAH Study shows that local treatments of advanced or inoperable Hepatocellular Cancer (HCC) with SIR-Spheres Y-90 resin microspheres did not lead to a planned superiority difference in overall   survival compared ...
Source: PR Newswire
Date: April, 24 2017 02:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-08-1323.05523.05523.05523.055550
2018-08-10N/A23.572N/AN/A0
2018-08-09N/A23.572N/AN/A0
2018-08-08N/A23.572N/AN/A0
2018-08-0723.57223.57223.57223.572184

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-07-03200200100.0000Short
2018-06-18100100100.0000Short
2018-06-0410043023.2558Cover
2018-05-23200200100.0000Short
2018-05-222525100.0000Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on SXMDF.


About Sirtex Medical Ltd. (OTC: SXMDF)

Logo for Sirtex Medical Ltd. (OTC: SXMDF)

Not available

 

Contact Information

 

 

Current Management

  • Michael Mangano / President

Current Share Structure

  • Market Cap: $1,215,814,400 - 03/09/2018
  • Issue and Outstanding: 56,080,000 - 09/05/2013

 



Daily Technical Chart for (OTC: SXMDF)

Daily Technical Chart for (OTC: SXMDF)


Stay tuned for daily updates and more on (OTC: SXMDF)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: SXMDF)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in SXMDF is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of SXMDF and does not buy, sell, or trade any shares of SXMDF. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/